JOHNSON & JOHNSON JNJ revenue by segment, product and geography
In its fiscal year ending 2025-12-31, JOHNSON & JOHNSON reported revenue across 2 business segments; the largest, Innovative Medicine, was $60.4B, 64.1% of the filed sum (+6.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Innovative Medicine$60.4B64.1%+6.0% yoy
- Med Tech$33.8B35.9%+6.1% yoy
Members sum to the consolidated $94.2B for this period.
- United States$53.8B57.1%+6.9% yoy
- Outside the United States$40.4B42.9%+5.0% yoy
Members sum to the consolidated $94.2B for this period.
- Innovative Medicine$16.4B64.7%+7.8% yoy
- Med Tech$8.93B35.3%+4.5% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.